keyword
MENU ▼
Read by QxMD icon Read
search

Psoriatic AND arthritis

keyword
https://www.readbyqxmd.com/read/30535992/outcome-of-pregnancy-in-women-with-psoriatic-arthritis-compared-to-healthy-controls
#1
Ari Polachek, Inbal Polachek Shlomi, Karen Spitzer, Daniel Pereira, Justine Yang Ye, Vinod Chandran, Carl A Laskin, Dafna D Gladman
OBJECTIVES: The mean age at onset of psoriatic arthritis (PsA) ranges between the 4th-6th decades of life. However, little is known about fertility and pregnancy outcome in PsA patients. The aim of this study was to examine whether fertility and pregnancy outcome of PsA patients are different from healthy controls and to evaluate PsA and psoriasis disease activity perception during pregnancy and the year postpartum. METHODS: A questionnaire-based study, including demographic, fertility, pregnancy outcome, and disease activity questions, was conducted in PsA patients and healthy controls...
December 7, 2018: Clinical Rheumatology
https://www.readbyqxmd.com/read/30535825/preliminary-validation-of-the-simplified-psoriatic-arthritis-radiographic-score-spars
#2
Fausto Salaffi, Marina Carotti, Eleonora Di Donato, Marco Di Carlo, Michele Maria Luchetti, Luca Ceccarelli, Andrea Giovagnoni
OBJECTIVE: To develop and validate in a preliminary way a novel radiographic scoring system for psoriatic arthritis (PsA), called Simplified Psoriatic Arthritis Radiographic Score (SPARS). MATERIALS AND METHODS: Radiographs of hands and feet were obtained from consecutive PsA patients and assessed by two readers. For each joint (30 joints in the hands, ten joints in the feet), the combination of the erosions, joint narrowing space (JNS) and bony proliferation (BP) has been assessed, giving a value of 1 for erosions presence, 1 for JNS presence, and 1 for BP presence (SPARS score range, 0-120)...
December 7, 2018: Skeletal Radiology
https://www.readbyqxmd.com/read/30535654/to-what-extend-is-nail-ultrasound-discriminative-between-psoriasis-psoriatic-arthritis-and-healthy-subjects
#3
Esperanza Naredo, Iustina Janta, Ofelia Baniandrés-Rodríguez, Lara Valor, Michelle Hinojosa, Natalia Bello, Belén Serrano, Jesús Garrido
To assess the discriminative utility of nail features detected by B-mode (BM) and color Doppler (CD) ultrasound (US) between patients with psoriasis (PsO) and psoriatic arthritis (PsA) and healthy controls. Sixty patients with PsA, 21 patients with PsO, and 20 healthy controls were prospectively included. All patients underwent a dermatologic assessment and PsA patients also a rheumatologic assessment. All patients and controls underwent a US assessment of the finger nails that included a BM score for nail plate integrity and four different CD scores based on the amount and location of CD signals in the nail bed/matrix...
December 10, 2018: Rheumatology International
https://www.readbyqxmd.com/read/30533239/delayed-diagnosis-of-psoriatic-arthritis-mutilans-due-to-arthritis-prior-to-skin-lesion
#4
Takeshi Mochizuki, Katsunori Ikari, Ken Okazaki
Psoriatic arthritis (PsA) is a type of inflammatory arthritis characterized by cutaneous psoriasis, peripheral joint damage, axial joint damage, and enthesitis and is usually diagnosed after the appearance of psoriatic skin disease. PsA mutilans is relatively rare in Japan. In the present case, the patient was diagnosed with PsA with foot mutilans deformity only. Hand and spinal radiograph findings were unremarkable. As in the present case arthritis is occurred prior to the onset of skin lesion, we should make early diagnosis to prevent mutilans deformity...
2018: Case Reports in Rheumatology
https://www.readbyqxmd.com/read/30530442/concurrent-development-of-psoriatic-arthritis-drug-induced-interstitial-pneumonia-and-increased-anti-nuclear-antibodies-in-a-patient-with-psoriasis-vulgaris-undergoing-adalimumab-treatment
#5
Masahito Yasuda, Naoko Morimoto, Yukio Yonemoto, Noriaki Sunaga, Osamu Ishikawa
No abstract text is available yet for this article.
December 10, 2018: European Journal of Dermatology: EJD
https://www.readbyqxmd.com/read/30528570/smoking-but-not-alcohol-is-associated-with-risk-of-psoriasis-in-a-taiwanese-population-based-cohort-study
#6
Ying-Xiu Dai, Shih-Chun Wang, Yiing-Jenq Chou, Yun-Ting Chang, Tzeng-Ji Chen, Chung-Pin Li, Chen-Yi Wu
BACKGROUND: Alcohol consumption and smoking have long been suspected of increasing the risk of developing psoriasis. Most evidence to date has derived from cross-sectional or case-control studies. OBJECTIVE: We sought to investigate the effects of alcohol and smoking on incident psoriasis. METHODS: Alcohol consumption, smoking status, and other covariates were collected from four rounds (2001, 2005, 2009, and 2013) of the Taiwan National Health Interview Survey...
December 7, 2018: Journal of the American Academy of Dermatology
https://www.readbyqxmd.com/read/30528501/increased-risk-of-incident-thyroid-diseases-in-people-with-psoriatic-disease-a-cohort-study
#7
Shu-Hui Wang, Jui Wang, Yu-Sheng Lin, Tao-Hsin Tung, Ching-Chi Chi
BACKGROUND: The association between psoriasis and thyroid diseases was unclear. OBJECTIVE: To examine the risk of thyroid diseases in psoriasis patients. METHODS: We used Taiwan's National Health Insurance Research Database to conduct a nationwide cohort study. We examined the hazard ratio (HR) and 95% confidence interval (CI) for incident thyroid diseases in relation to psoriasis and psoriatic arthritis. RESULTS: We identified 13,266 patients with psoriatic arthritis (psoriasis arthritis group), 149,576 with psoriasis alone (psoriasis group), and 162,842 nonpsoriatic controls...
December 5, 2018: Journal of the American Academy of Dermatology
https://www.readbyqxmd.com/read/30527433/update-on-the-epidemiology-risk-factors-and-disease-outcomes-of-psoriatic-arthritis
#8
REVIEW
Dilek Solmaz, Lihi Eder, Sibel Zehra Aydin
Psoriatic arthritis (PsA) is a chronic inflammatory disease that affects different structures of the musculoskeletal system in addition to the skin and the nail. The complexity of the disease had been a barrier to understand the pathogenesis and define valid outcome tools; however, our understanding about the disease has considerably increased with time mainly because of the advances in imaging, new discoveries in genetics and underlying inflammatory pathways, and better understanding of the epidemiology of the disease and environmental risk factors...
April 2018: Best Practice & Research. Clinical Rheumatology
https://www.readbyqxmd.com/read/30526678/secukinumab-provides-sustained-pasdas-defined-remission-in-psoriatic-arthritis-and-improves-health-related-quality-of-life-in-patients-achieving-remission-2-year-results-from-the-phase-iii-future-2-study
#9
L C Coates, D D Gladman, P Nash, O FitzGerald, A Kavanaugh, T K Kvien, L Gossec, V Strand, L Rasouliyan, L Pricop, K Ding, S M Jugl, C Gaillez
BACKGROUND: Secukinumab has demonstrated sustained improvement in the signs and symptoms of psoriatic arthritis (PsA) over 2 years in the FUTURE 2 study (NCT01752634). This post hoc analysis assessed the ability of secukinumab to achieve Psoriatic Arthritis Disease Activity Score (PASDAS)-based remission or low disease activity (LDA) through 2 years among patients with PsA in the FUTURE 2 study. METHODS: PASDAS (cut-off scores: remission ≤ 1.9; LDA > 1...
December 7, 2018: Arthritis Research & Therapy
https://www.readbyqxmd.com/read/30526155/secukinumab-in-the-therapy-of-psoriasis-and-psoriatic-arthritis-a-safe-choice-in-clinical-practice
#10
Andrea Chiricozzi
No abstract text is available yet for this article.
December 8, 2018: Journal of Dermatological Treatment
https://www.readbyqxmd.com/read/30522944/spanish-registry-of-recent-onset-psoriatic-arthritis-reapser-study-aims-and-methodology
#11
Rubén Queiro, Ana Laiz, Daniel Seoane-Mato, Eva Galindez Agirregoikoa, Carlos Montilla, Hye Sang Park, Juan José Bethencourt Baute, Sagrario Bustabad, Jose A Pinto Tasende, Patricia Tejón, Beatriz Joven Ibáñez, Julio Ramírez, Andrea Cuervo, Juan D Cañete, Pilar Trenor Larraz, Carmen Ordás, Sara Alonso, Edilia García-Fernández, Elide Toniolo, Manuel José Moreno Ramos, María Dolores Beteta, Leticia Lojo Oliveira, Teresa Navío Marco, Laura Cebrián, Ceferino Barbazán, Francisco Maceiras, Jesús Rodriguez-Moreno, Martina Steiner, Santiago Muñoz-Fernández, Francisco Javier Nóvoa Medina, Manuel León, Esteban Rubio, Julio Medina Luezas, María Dolores Sánchez-González, Marta Arévalo, Jordi Gratacós, José Miguel Senabre, José Carlos Rosas, Gregorio Santos Soler, Juan Carlos Nieto-González, Carlos González, Alejandra López Robles, Carolina Álvarez Castro, María Dolores Ruiz Montesino, Vicenç Torrente-Segarra, Cristina Fernández-Carballido, María Paz Martínez-Vidal, Vega Jovani, Ana Urruticoechea-Arana, Yolanda Cabello Fernández, María Dolores Toledo, Raquel Almodóvar, Miguel Ángel Belmonte-Serrano, Irene Notario Ferreira, Enrique Raya Álvarez
AIMS: To describe the methodology of REAPSER (Spanish Registry of Recent-onset Psoriatic Arthritis), its strengths and limitations. The aim of this study is to identify prognostic factors for the clinical and radiographic course in a cohort of patients with psoriatic arthritis (PsA) diagnosed within 2years of symptom evolution. METHODS: Multicenter, observational and prospective study (with 2-year follow-up including annual visits). Baseline visit intended to reflect patient situation before the disease course was modified by treatments prescribed in rheumatology departments...
December 3, 2018: Reumatología Clinica
https://www.readbyqxmd.com/read/30522501/improved-patient-reported-outcomes-in-patients-with-psoriatic-arthritis-treated-with-abatacept-results-from-a-phase-3-trial
#12
Vibeke Strand, Evo Alemao, Thomas Lehman, Alyssa Johnsen, Subhashis Banerjee, Harris A Ahmad, Philip J Mease
BACKGROUND: To explore the effect of abatacept treatment on patient-reported outcomes (PROs) in psoriatic arthritis (PsA). METHODS: Patients with PsA were randomised (1:1) to subcutaneous abatacept 125 mg weekly/placebo for 24 weeks with early escape (EE) to open-label abatacept (week 16). Adjusted mean changes from baseline to weeks 16 (all patients) and 24 (non-EE responders) in Health Assessment Questionnaire-Disability Index (HAQ-DI), Short Form-36 (SF-36; physical and mental component summary and domains), Dermatology Life Quality Index and Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) were evaluated...
December 6, 2018: Arthritis Research & Therapy
https://www.readbyqxmd.com/read/30517715/validation-of-new-potential-targets-for-remission-and-low-disease-activity-in-psoriatic-arthritis-in-patients-treated-with-golimumab
#13
Laura C Coates, Proton Rahman, Eliofotisti Psaradellis, Emmanouil Rampakakis, Brendan Osborne, Allen J Lehman, Francois Nantel
Objectives: Treat to target recommendations for PsA state that the target of treatment should be remission or, at the very least, low disease activity. Different clinical indexes have been proposed to define these disease states including the minimal disease activity criteria and the Disease Activity Index for PsA (DAPSA) scores, which have 7 and 4-5 domains, respectively. Using a Canadian cohort, the objectives were to calculate the proportion of patients achieving these criteria, their prognostic value and the overall patient impact of these disease states...
December 4, 2018: Rheumatology
https://www.readbyqxmd.com/read/30513782/sarcopenia-in-patients-with-rheumatic-diseases-prevalence-and-associated-risk-factors
#14
Michele Barone, Maria Teresa Viggiani, Maria Grazia Anelli, Rosalinda Fanizzi, Orsola Lorusso, Giuseppe Lopalco, Luca Cantarini, Alfredo Di Leo, Giovanni Lapadula, Florenzo Iannone
The prevalence of sarcopenia in rheumatic diseases has been evaluated in single diseases using various diagnostic approaches, generating conflicting data on the pathogenetic mechanism(s). Herein, we evaluated both muscle mass index (MMI) and muscle strength to assess sarcopenia and presarcopenia in patients with rheumatoid arthritis (RA), psoriatic arthritis (PsA), and ankylosing spondylitis (AS). Moreover, we evaluated the possible impact of disease/patient-related characteristics, therapeutic regimens, and nutritional aspects on sarcopenia...
December 1, 2018: Journal of Clinical Medicine
https://www.readbyqxmd.com/read/30511296/treating-psoriatic-arthritis-to-target-discordance-between-physicians-and-patients-assessment-non-adherence-and-restricted-access-to-drugs-precluded-therapy-escalation-in-a-real-world-cohort
#15
Manoela Fantinel Ferreira, Charles Lubianca Kohem, Ricardo Machado Xavier, Everton Abegg, Otavio Silveira Martins, Marcus Barg Resmini, Ariele Lima de Mello, Franciele de Almeida Menegat, Vanessa Hax, Andrese Aline Gasparin, Claiton Viegas Brenol, Nicole Pamplona Bueno de Andrade, Daniela Viecceli, João Carlos Tavares Brenol, Penélope Esther Palominos
The treat-to-target strategy (T2T) was associated with better outcomes in psoriatic arthritis (PsA) compared to standard care in clinical trials. This study aimed to analyze factors precluding treatment optimization in a T2T strategy conducted in a real-world cohort of PsA patients. A retrospective cross-sectional study nested in a cohort was conducted. Medical records of patients ≥ 18 years old, fulfilling CASPAR criteria and with at least one visit in the PsA clinic, were reviewed. Demographic data, current medication, and minimal disease activity (MDA) criteria were recorded...
December 3, 2018: Clinical Rheumatology
https://www.readbyqxmd.com/read/30507131/a-drug-with-lipophilicity-dependent-potency-can-be-metabolically-stable-discovery-of-a-potent-and-selective-retinoic-acid-receptor-related-orphan-receptor-c2-rorc2-inverse-agonist-as-an-orally-bioavailable-anti-inflammatory-agent
#16
Yibing Wang, Hong Liu
IL-17 drives an amplification mechanism in inflammatory diseases such as psoriasis, psoriatic arthritis, and ankylosing spondylitis. The production of IL-17 depends on the activity of RORC2 in immune cells, which suggests that RORC2 inverse agonists are capable of anti-inflammatory therapy by reducing IL-17 levels. However, oral delivery of inverse agonists remains a challenge since the binding pocket of RORC2 prefers to accommodate lipophilic ligands, which tend to have poor metabolic stability. This Viewpoint discusses recent results published in this journal that identified a potent, selective, and orally bioavailable RORC2 inverse agonist as an anti-inflammatory agent, optimized from a high-throughput screening (HTS) hit through a combination of de novo and structure-guided design...
December 3, 2018: Journal of Medicinal Chemistry
https://www.readbyqxmd.com/read/30505012/sleep-disorders-in-patients-with-psoriatic-arthritis-and-psoriasis
#17
Magdalena Krajewska-Włodarczyk, Agnieszka Owczarczyk-Saczonek, Waldemar Placek
Objectives: To assess and measure occurrence of sleep disorders in patients with psoriatic arthritis (PsA) and psoriasis (Ps). Material and methods: The study included 62 patients with psoriatic arthritis and 52 patients with psoriasis. The measurement of sleep quality was conducted using the Pittsburgh Sleep Quality Index (PSQI), the evaluation of fatigue by the fatigue subscale of the FACIT-F questionnaire and the patient's quality of life by the Health Assessment Questionnaire (HAQ)...
2018: Reumatologia
https://www.readbyqxmd.com/read/30504983/a-case-of-ostraceous-psoriasis-with-psoriatic-arthritis-in-an-aids-patient
#18
Minkee Park, Myeong Jin Park, Mi Soo Choi, Chan Hee Nam, Byung Cheol Park, Seung Phil Hong, Myung Hwa Kim
Human immunodeficiency virus (HIV) infection may present with severe and atypical cutaneous diseases. Psoriasis also can develop in HIV patients associated with immune dysfunction and be presented as more severe and atypical manifestation. Furthermore, treatment of psoriasis in HIV patients can be complex and challenging. Herein, we report the case of a 50-year-old male with a 9-year history of HIV infection who developed an uncommon clinical variant of psoriasis with psoriatic arthritis and we discuss a possible pathogenesis of this autoimmune disease and possible treatment...
November 2018: Indian Journal of Dermatology
https://www.readbyqxmd.com/read/30504477/what-is-axial-psoriatic-arthritis
#19
EDITORIAL
Joy Feld, Vinod Chandran, Dafna D Gladman
No abstract text is available yet for this article.
December 2018: Journal of Rheumatology
https://www.readbyqxmd.com/read/30499418/combination-therapy-of-apremilast-and-biologic-agent-as-a-safe-option-of-psoriatic-arthritis-and-psoriasis
#20
Samy Metyas, Christopher Tomassian, Ramy Messiah, Tina Gettas, Christina Chen, Anne Quismorio
Psoriasis is a chronic immune-mediated inflammatory dermatologic condition that is often associated with psoriatic arthritis. There are multiple regimens for the treatment of psoriasis including disease modifying anti rheumatics drugs, biologic agents, phototherapy, topical retinoid and steroids creams, as well as apremilast. Apremilast is an oral phosphodiesterase inhibitor that was approved by the FDA in March 2014 for the treatment of psoriatic arthritis and September 2014 for the treatment of moderate to severe plaque psoriasis...
November 29, 2018: Current Rheumatology Reviews
keyword
keyword
164710
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"